Clinical Trial Update: Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in combination with platinum/gemcitabine for first-line advanced urothelial carcinoma is ongoing, with status not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Urothelial Carcinoma, Anlotinib | Phase 2 | Status: UNKNOWN